MedPath

Recurrence of Liver Malignancy After Ischemia/Reperfusion Injury

Completed
Conditions
Liver Cancer
Liver Injury
Malignancy
Ischemic Reperfusion Injury
Cancer Recurrence
Interventions
Procedure: selective hepatic vascular exclusion
Procedure: semielective hepatic vascular exclusion
Registration Number
NCT04257240
Lead Sponsor
Aretaieion University Hospital
Brief Summary

Severe ischemic changes of the liver remnant after hepatectomy could expedite tumor recurrence on the residual liver. Our study aimed at assessing the effect of warm ischemic/reperfusion (I/R) injuries on surgery-to-local recurrence interval and patient overall survival, during major hepatectomies under inflow and outflow vascular control.

Detailed Description

One hundred and eighteen patients were subjected to liver resection under total inflow and outflow vascular clamping and were assigned as study group. These individuals were retrospectively matched to 112 counterparts, who underwent liver surgery applying inflow and outflow vascular clamping only of the segment harboring the tumor, sparing the liver remnant from any I/R injury (control group). The two cohorts were compared regarding recurrence-free survival and overall survival.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
230
Inclusion Criteria
  • Adult patients
  • American Society of Anesthesiologists (ASA) distribution I to III
  • Patients scheduled for major liver resection (≥3 segments)
Exclusion Criteria
  • patients with extrahepatic disease
  • patients with metastatic liver tumors

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
study groupselective hepatic vascular exclusionpatients subjected to major hepatectomy with vascular control of blood inflow and outflow of the whole liver
control groupsemielective hepatic vascular exclusionpatients subjected to major hepatectomy by selectively clamping the portal and hepatic vessels only of the lobe harboring the tumor
Primary Outcome Measures
NameTimeMethod
time to malignant recurrencefrom time of operation until time of malignant recurrence, assessed up to 15 years

recurrence-free survival

time to deathfrom time of operation until time of death, assessed up to 20 years

overall survival

Secondary Outcome Measures
NameTimeMethod
aspartate aminotrasferase (AST) levelssecond postoperative day

aspartate aminotransferase levels

© Copyright 2025. All Rights Reserved by MedPath